Cancer

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…

11 hours ago

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency…

11 hours ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),…

11 hours ago

Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health securityStrategic…

11 hours ago

Health Canada cannabis guidance exposes “absurd” education gap in healthcare

- Apothecare calls for medical cannabis education to be integrated into clinical training and standard practice, not left to patients…

11 hours ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and…

11 hours ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a…

11 hours ago

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for…

11 hours ago

Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in…

13 hours ago

Protai to showcase groundbreaking AIMS™ drug discovery platform and best-in-class PRT001 KAT6A degrader results at spring 2026 global conferences.

TEL AVIV, Israel, Feb. 10, 2026 /PRNewswire/ -- Protai, www.protai.bio, an AI drug discovery startup, announced its participation in a series of…

14 hours ago